Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | RB1 | P06400 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12198083 | 0.90 | ACKR3 (0.56) | ACKR3ADRA1DADRA1AADRA1BBRD3 | |
| SCHEMBL2810726 | 0.80 | BRD3 (0.45) | ACKR3BRD3 | |
| SCHEMBL1989585 | 0.80 | DHODH (0.48) | ACKR3AURKASIRT1KDM4E | |
| SCHEMBL1989539 | 0.80 | ACKR3 (0.40) | ACKR3ADRA1DADRA1AADRA1B | |
| SCHEMBL2813168 | 0.80 | L3MBTL1 (0.47) | ACKR3SIRT1KDM4E | |
| SCHEMBL1992479 | 0.75 | NISCH (0.44) | ACKR3CHRNA7AURKAKDM4E | |
| SCHEMBL2810212 | 0.75 | HTR2A (0.47) | ACKR3ADRA1DADRA1AADRA1BBRD3 | |
| SCHEMBL2814467 | 0.74 | KIF11 (0.43) | ACKR3SIRT1KDM4E | |
| SCHEMBL18557396 | 0.72 | ACKR3 (0.39) | ACKR3ADRA1DADRA1AADRA1BBRD3 | |
| SCHEMBL1993492 | 0.72 | SIGMAR1 (0.41) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | ACKR3 1117/4885ADRA1D 177/4885ADRA1A 284/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | ACKR3 1117/4885ADRA1D 177/4885ADRA1A 284/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | ACKR3 1117/4885ADRA1D 177/4885ADRA1A 284/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | ACKR3 1117/4885ADRA1D 177/4885ADRA1A 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.